Mobile app to improve treatment for ovarian cancer
Value-based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2)
This study tests a mobile app that helps women with advanced ovarian cancer track their health and get personalized support from their doctors.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | Female |
| Sponsor | Jonsson Comprehensive Cancer Center Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT05523700 on ClinicalTrials.gov |
What this trial studies
This study evaluates a mobile application designed to enhance patient-reported health outcomes for individuals diagnosed with advanced ovarian, fallopian tube, and primary peritoneal cancer. The app integrates clinical data from medical records and continuously captures patient-reported outcome measures (PROMs) to inform healthcare providers about necessary interventions. By utilizing AI-driven care pathways, the application generates personalized recommendations based on individual risk profiles and health outcomes, facilitating ongoing monitoring and support for patients. It also offers educational resources, appointment reminders, and nutritional and mental health support.
Who should consider this trial
Good fit: Ideal candidates include females aged 18 and older who have been diagnosed with ovarian cancer and are undergoing active treatment.
Not a fit: Patients who are under 18 years old or have concurrent non-gynecologic cancers requiring active treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the quality of care and health outcomes for patients with ovarian cancer.
How similar studies have performed: Other studies utilizing mobile applications for chronic disease management have shown promising results, indicating potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Female ≥18 years of age at Screening Visit. 2. Diagnosed with ovarian cancer, fallopian tube, or primary peritoneal cancer 3. Undergoing active treatment at some point during the study period including chemotherapy, immunotherapy, targeted agent or hormonal therapy. If active treatment has not yet started at time of screening, active treatment must be anticipated to begin within 30 days of enrollment. 4. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study. 5. Access to IOS or Android-based smart phone Exclusion Criteria: 1. Unwilling or unable to adhere to the protocol 2. Unwilling or unable to adhere to the informed consent 3. Age \<18yo 4. Concurrent non-gynecologic cancer diagnosis requiring active treatment at enrollment 5. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Where this trial is running
Los Angeles, California
- UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California, United States (Recruiting)
Study contacts
- Principal investigator: Tiffany Lai, MD — University of California, Los Angeles
- Study coordinator: Jenny Lester, MPH
- Email: jlester@mednet.ucla.edu
- Phone: 310-794-9727
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.